Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Reported Earlier, AVITA Medical Announces Leadership Transition With Cary Vance As Interim CEO And Preliminary Q3 Revenue Of $17M

Author: Benzinga Newsdesk | October 17, 2025 01:02am
  • Board Chairman Cary Vance appointed Interim CEO
  • Board member Jan Stern Reed appointed Lead Independent Director
  • Third quarter 2025 preliminary revenue expected to be approximately $17 million

Posted In: RCEL

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist